menu
    • menu
    [{"orgOrder":0,"company":"Tome Biosciences","sponsor":"Andreessen Horowitz","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery","graph3":"Tome Biosciences","amount2":0.12,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Hepatology","amount2New":0.12,"dosageForm":"","sponsorNew":"Tome Biosciences \/ Andreessen Horowitz","highestDevelopmentStatusID":"2","companyTruncated":"Tome Biosciences \/ Andreessen Horowitz"},{"orgOrder":0,"company":"Tome Biosciences","sponsor":"Genevant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform","graph3":"Tome Biosciences","amount2":0.11,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Hepatology","amount2New":0.11,"dosageForm":"","sponsorNew":"Tome Biosciences \/ Tome Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Tome Biosciences \/ Tome Biosciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Tome Biosciences

    Menu

    Tome Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tome Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Tome Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Discovery Platform

                            Recipient : Genevant Sciences

                            Deal Size : $114.3 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Genevant Sciences Partners with Tome Biosciences for Gene Editing in Rare Liver Disorder

                            Details : Genevant and Tome will develop an in vivo gene editing treatment for a rare liver disorder using LNP and programmable genomic integration technologies.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 16, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Discovery Platform

                            Recipient : Genevant Sciences

                            Deal Size : $114.3 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tome Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Tome Biosciences

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Discovery

                            Sponsor : Andreessen Horowitz

                            Deal Size : $118.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platfo...

                            Details : The Company intends to use the net proceeds to develop integrative gene therapies for monogenic liver diseases and cell therapies for autoimmune diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 12, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Discovery

                            Sponsor : Andreessen Horowitz

                            Deal Size : $118.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth